-
Aponermin for Injection Approved for Marketing by China NMPA
2023-11-02
Recently, the Aponermin for Injection (Chinese trade name:沙艾特) of Wuhan HITECK biopharmaceutical Co., Ltd. is approved by China NMPA.
-
Children's Zibei Xuanfei Syrup Approved for Marketing
2023-10-19
Recently, the Category 1.1 innovative traditional Chinese medicine Children's Zibei Xuanfei Syrup of Jianmin Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA.
-
Tongluo Mingmu Capsules Approved for Marketing by China NMPA
2023-10-19
Recently, the Category 1.1 innovative traditional Chinese medicine Tongluo Mingmu Capsules of Shijiazhuang Yiling Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Ritlecitinib Tosylate Capsules Approved for Marketing
2023-10-19
Recently, the Category 1 innovative drug Ritlecitinib Tosylate Capsules (trade name: LITFULO ®) of Pfizer Inc. is approved for marketing through priority review and approval procedures by China NMPA.
-
Deucravacitinib Tablets Approved for Marketing by China NMPA
2023-10-19
Recently, the category 1 innovative product Deucravacitinib Tablets (trade name: Sotyktu) of Bristol Myers Squibb is approve for marketing by China NMPA.
-
NMPA Becomes the Applicant for PIC/S
2023-11-09
In late September 2023, the National Medical Products Administration(NMPA) submitted formal application to the Pharmaceutical Inspection Co-operation Scheme (PIC/S).
